Bris­tol My­ers wins a big bet as their PhI­II au­toim­mune drug beat out block­buster Ote­zla — and that could cost Am­gen dear­ly

Bris­tol My­ers Squibb $BMY bet big on a Phase III pso­ri­a­sis pro­gram for its TYK2 con­tender deu­cravac­i­tinib (BMS-986165). And to­day they’re de­clar­ing their heavy­weight con­tender …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER